Allarity Therapeutics A/S

Headquarters: Horsholm, Denmark

Employees: 14

CEO: Mr. Stefano R. Carchedi

show_chart OMX: ALLR -26.54%

Market Cap

kr932.6 Million

SEK as of Dec. 1, 2021

US$103.1 Million

history Market Cap History

Allarity Therapeutics A/S market capitalization over time

Evolution of Allarity Therapeutics A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Allarity Therapeutics A/S

Detailed Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.

Stocks & Indices

Allarity Therapeutics A/S has the following listings and related stock indices.

Stock: OMX: ALLR



Venlighedsvej 1

Horsholm, 2970


Phone: 45 88 74 24 14